INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 10/3/2012
Health Canada Approves Esbriet® as First Treatment for Fatal Lung Disease
- Novel oral therapy slows progression of IPF in mild to moderate patients -
- Esbriet expected to be available on January 1, 2013 -
- Company to provide more details on third quarter earnings call -
INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/24/2012
Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis
24th September 2012 13:16 IST
Ingelheim, Germany (Business Wire (Business Wire India))
For NON-U.S Health Media Only
INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/20/2012
Thalidomide Eases Cough in Lung Fibrosis Patients
INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/10/2012
FIBROGEN ANNOUNCES PRESENTATION OF UPDATED RESULTS AT EUROPEAN RESPIRATORY SOCIETY ANNUAL CONGRESS
San Francisco, CA - September 5, 2012
INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/4/2012
InterMune Reports New Analyses from the RECAP Study of Esbriet® (pirfenidone) at ERS
INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 7/9/2012
A Placebo-Controlled Randomized Trial of Warfarin in
Idiopathic Pulmonary Fibrosis
Imre Noth1, Kevin J. Anstrom2, Sara Bristol Calvert2, Joao de Andrade3, Kevin R. Flaherty4,
